Eli Lilly and Company $LLY Stake Raised by Trinity Legacy Partners LLC

Key Points

• Trinity Legacy Partners LLC increased its stake in Eli Lilly by 937.5% during the second quarter, holding 2,905 shares valued at approximately $2.3 million.
• Eli Lilly reported strong second-quarter results with $6.31 EPS, exceeding analysts' expectations, and a 37.6% increase in year-over-year revenue.
• Institutional investors now hold 82.53% of Eli Lilly's shares, with significant increases from firms like PNC Financial Services and Vanguard Group.

Trinity Legacy Partners LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 937.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,905 shares of the company's stock after buying an additional 2,625 shares during the period. Trinity Legacy Partners LLC's holdings in Eli Lilly and Company were worth $2,295,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP grew its position in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after buying an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after buying an additional 682,203 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Eli Lilly and Company in the first quarter worth approximately $4,613,912,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.6%

Shares of NYSE:LLY opened at $820.69 on Friday. The firm has a fifty day moving average of $734.03 and a two-hundred day moving average of $766.34. The firm has a market capitalization of $776.75 billion, a P/E ratio of 53.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Leerink Partners restated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their price objective for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. Berenberg Bank reaffirmed a "hold" rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.